Martin Hutchings, EHA 2018 – ECHELON-1 trial and chemotherapy regimens in Hodgkin’s lymphoma

Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changingПодробнее

5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphomaПодробнее

ECHELON-1 Trial: Significance in Hodgkin LymphomaПодробнее

Dr. Hutchings on the Aim of the ECHELON-1 Study in Hodgkin LymphomaПодробнее

Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHLПодробнее

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HLПодробнее

Common Implications in Treating Patients With Advanced Hodgkin LymphomaПодробнее

Martin Hutchings | EHA 2018 | Key outcomes of the ECHELON-1 sub-analysisПодробнее

Dr. Hutchings on Subgroup Analysis of ECHELON-1 in Hodgkin LymphomaПодробнее

ECHELON-1 Trial Shows Continued Efficacy Over Time in Hodgkin LymphomaПодробнее

Current landscape and future prospects for Hodgkin lymphoma treatmentПодробнее

GHSD HD18 study: reducing chemotherapy toxicity in advanced stage Hodgkin lymphomaПодробнее

Subcutaneous epcoritamab in R/R B-cell NHLПодробнее

EBMT 2018: Updates on advanced Hodgkin lymphoma treatmentПодробнее

Dr. Kaplan on the Phase III ECHELON-1 Trial in Hodgkin LymphomaПодробнее

Martin Dreyling | EHA 2018 | Overview of EHA presentations in indolent lymphomaПодробнее

Updated 3-Year Findings of ECHELON-1 Trial Presented for Classical Hodgkin LymphomaПодробнее

ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphomaПодробнее

Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin LymphomaПодробнее